Bristol Myers Squibb Halts Clinical Development of Prothena’s PRX019
Bitget2026/10/29 20:14- Bristol Myers Squibb notified Prothena on October 28, 2026, it would stop clinical development of PRX019 following a strategic review.
- The license, signed in May 2024 with an $80 million upfront payment, will terminate on January 28, 2027.
- Termination eliminates eligibility for up to $617.5 million in development, regulatory and sales milestones, as well as tiered royalties.
- Previously reported Phase 1 results from the first half of 2026 showed favorable safety and tolerability, meeting prespecified biological-response targets.
- Bristol Myers Squibb continues moponetug’s Phase 2 Alzheimer’s trial, with up to $562.5 million in regulatory and sales milestones remaining available.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
